Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Urine peptides enable non-invasive differential diagnosis of nodular diabetic nephropathy.

Diabetes research and clinical practice·2026

Same author

Cyclosporin a- versus tacrolimus-specific lesions in calcineurin inhibitor nephrotoxicity.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026

Same author

A retrospective study of CKDu progression in Sri Lanka: analysis of kidney biopsies and association with risk factors.

BMC nephrology·2026

Same author

Associations between CT radiomics analyses and kidney biopsy in patients with kidney disease.

BMC nephrology·2026

Same author

Impact of sampling side of peritoneal biopsies on peritoneal thickness and histopathological diagnosis-A quantitative histological study in body donors.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026

Same author

[Histology and more-modern nephropathology].

Innere Medizin (Heidelberg, Germany)·2026

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Thrombotic microangiopathy: new insights.

Kerstin Benz¹, Kerstin Amann

¹Department of Pediatrics, University of Erlangen-Nürnberg, Erlangen, Germany.

Current Opinion in Nephrology and Hypertension

|February 27, 2010

Summary

Thrombotic microangiopathy (TMA) involves kidney damage from microvascular thrombosis. New insights into atypical hemolytic uremic syndrome (aHUS) reveal complement system disturbances, with eculizumab showing therapeutic promise.

More Related Videos

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Related Experiment Videos

Last Updated: Jun 15, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Area of Science:

Nephrology
Hematology
Pathology

Background:

Thrombotic microangiopathy (TMA) encompasses various microvascular thrombosis syndromes.
These include atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), and conditions related to hypertension, drugs, autoimmune diseases, or rejection.

Purpose of the Study:

To discuss new aspects of kidney involvement in TMA, focusing on epidemiology, pathogenesis, and morphology.
To highlight recent pathophysiological insights and therapeutic advancements for TMA, particularly in aHUS.

Main Methods:

Review of current literature on TMA, focusing on genetic and molecular studies.
Emphasis on understanding the role of the complement system in aHUS pathogenesis.
Discussion of therapeutic options, including recent developments like eculizumab.

Main Results:

TMA in the kidney is characterized by endothelial damage and vascular changes.
Pathogenesis of aHUS involves deficiencies and disturbances in the complement system.
Eculizumab has emerged as a promising therapeutic option for aHUS.

Conclusions:

Kidney manifestations in HUS/TTP require clinical and morphological differentiation from other diseases.
Genetic and molecular studies clarify the pathogenesis of TMA in aHUS (complement system) and TTP (ADAMTS13).
Understanding these mechanisms aids in differential diagnosis and treatment strategies.